Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HY-111996
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HY-111996 is a small molecule drug candidate that acts as a modulator of Kv3 voltage-gated potassium channels. It is referenced in the literature as "Kv3 modulator 1" and has been investigated for its effects on central nervous system disorders, particularly schizophrenia. The compound's mechanism involves modulation of the Kv3 family of potassium channels, which are important for regulating neuronal excitability and fast-spiking interneuron function. Clinical trials have evaluated its safety, tolerability, and pharmacokinetics in patients with schizophrenia[2][7][3].
- Other names
- Kv3 modulator 1Kv-3 modulator 1Kv 3 modulator 1Compound X (from patent WO2018020263A1)
02
Targets
KCNC4 (Potassium voltage-gated channel subfamily C member 4)
Beyond the preview
Go deeper on HY-111996.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HY-111996.